J&J | JNJ - Przychody Ze Sprzedaży





Obroty Zmiana Data
AbbVie USD 15B 1.62B 2026-03
Abbott USD 12.59B 1.43B 2026-06
Amgen USD 8.62B 1.28B 2026-03
AstraZeneca USD 15.29B 213M 2026-03
Baxter International USD 2.7B 270M 2026-03
Bayer EUR 13.41B 1.97B 2026-03
Becton, Dickinson and Co. USD 4.7B 600M 2026-03
Biogen USD 2.25B 30M 2026-03
Boston Scientific USD 5.2B 90M 2026-03
Bristol-Myers Squibb USD 11.49B 1.01B 2026-03
CONMED USD 317M 56.2M 2026-03
Cooper Companies USD 1.08B 57.4M 2026-03
Dexcom USD 1.19B 70M 2026-03
Edwards Lifesciences USD 1.65B 80M 2026-03
Eli Lilly USD 19.8B 500M 2026-03
Gilead Sciences USD 7B 930M 2026-03
GlaxoSmithKline GBP 7.63B 991M 2026-03
Globus Medical USD 759.85M 66.55M 2026-03
Insulet USD 761.7M 22.1M 2026-03
Integra LifeSciences USD 391.9M 43M 2026-03
Intuitive Surgical USD 2.89B 120M 2026-06
J&J USD 25.31B 1.21B 2026-06
Medtronic USD 9.8B 800M 2026-03
Merck USD 16.29B 110M 2026-03
Merit Medical Systems USD 381.9M 12M 2026-03
Novartis USD 14.41B 1.3B 2026-06
Pfizer USD 14.5B 3.08B 2026-03
Regeneron Pharmaceuticals USD 3.6B 280M 2026-03
Roche Holding CHF 15.65B 274.5M 2025-12
Sanofi EUR 11.24B 60M 2026-03
Stryker USD 6B 1.2B 2026-03
Tandem Diabetes Care USD 247.22M 43.18M 2026-03
Teva Pharmaceutical Industries USD 11.77B 2.86B 2026-03
Vertex Pharmaceuticals USD 2.99B 200M 2026-03
Zimmer Biomet Holdings USD 2.09B 150M 2026-03
Zoetis USD 2.3B 100M 2026-03